Active Ingredient(s):Pegloticase FDA Approved: * September 14, 2010 Pharm Company: *SAVIENT PHARMS Category:Gout
Pegloticase (trade name Krystexxa) is a medication for the treatment of severe, treatment-refractory, chronic gout. It is a third line treatment in those in whom other treatments are not tolerated. The drug is administered by infusion intravenously.
It was developed by Savient Pharmaceuticals. It was approved in the United States in 2010, after two clinical trials found it lowered uric acid levels and reduced deposits of uric acid cryst...
* May have multiple approval dates, manufacturers, or labelers.